Jannick Dorresteijn
0000-0002-0190-8526
University Medical Center Utrecht
3 papers found
Refreshing results…
Including measures of chronic kidney disease to improve cardiovascular risk prediction by SCORE2 and SCORE2-OP
Residual cardiovascular risk reduction guided by lifetime benefit estimation in patients with symptomatic atherosclerotic disease: effectiveness and cost-effectiveness
Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial
Missing publications? Search for publications with a matching author name.